News

The grant will support continued preclinical research on microRNA targeting in cardiovascular disease and help to establish a novel model system of chronic heart failure. The research aims

The company expects to conclude the Phase II trials in early next year. Lightlake intends to conduct Phase III trial at Imperial College London and other international institutions.

The results of the studies showed that the company’s RSV vaccine induces protective immunity in mice without eliciting the enhanced respiratory disease that has caused other RSV vaccine

The trial evaluated patients with locally advanced or metastatic breast cancer who had received one prior chemotherapy regimen were treated with weekly bavituximab and docetaxel. In a separate

The company has earned gross profit of $172.62m, compared to gross profit of $178.51m, for the same period last year. Hikma’s operating profit for the first quarter ended

The IND was filed by D-Pharm’s co-development partner in South Korea, Yungjin Pharmaceutical (YJP). YJP gets license to develop, register and market DP-b99 from D-Pharm in South Korea

Botox is indicated as a treatment for urinary incontinence due to detrusor overactivity linked with a neurologic condition like, SCI, MS in adults patients who have an inadequate

In total, the company has recruited 72 patients in the trial and expects to conclude treatment by its stipulated time line. RGN-259, a sterile, preservative-free topical eye drop

EpiPen and EpiPen Jr Auto-Injectors are intended for immediate self administration as emergency supportive therapy only. According to the guidelines given by the National Institute of Allergy and